Your session is about to expire
← Back to Search
Combination Therapy for Glioblastoma
Study Summary
This trial is studying the side effects of using partial brain radiation therapy, temozolomide, chloroquine, and tumor treating fields therapy to treat patients with newly diagnosed glioblastoma.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have been cancer-free for 5 years, except for certain skin cancers and early-stage cancers.I have been diagnosed with gliomatosis cerebri.My brain cancer has spread to other parts of my body.My tumor is located in the lower part of my brain.I have a known G6PD deficiency.My kidney function, measured by creatinine clearance, is adequate.My condition is recurrent glioblastoma.I have had chemotherapy or radiosensitizers for head/neck cancer, but not temozolomide.I have been diagnosed with a grade IV brain tumor.I have signed the consent form for this study.I have not used specific cancer treatments like bevacizumab or Gliadel wafers for my tumor.I have fully recovered from any surgery or its complications before joining.My hemoglobin level is at least 9.0 g/dL, possibly after receiving treatment.I've had radiation on my head or neck, not for T1 glottic or non-melanoma skin cancer, with overlapping treatment areas.I am using birth control as required, if I can have children.I had an MRI within 3 days after surgery or at least 2 weeks later.I am able to care for myself but may not be able to do active work.I have only had surgery for my glioblastoma; no other treatments except BCNU wafer.I am a woman able to have children and have a recent negative pregnancy test.
- Group 1: Treatment (radiation therapy, temozolomide, chloroquine, TTF)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has this research ever been done before?
"Currently, 212 trials of 3-Dimensional Conformal Radiation Therapy are active in 937 cities and 43 nations. This clinical trial was first initiated by Schering-Plough back in 2002 with 60 participants to achieve Phase 2 drug approval status. In the two decades that have followed, 396 additional studies on this therapy have been completed."
What conditions are ameliorated by 3-Dimensional Conformal Radiation Therapy?
"3-Dimensional Conformal Radiation Therapy can be prescribed as a course of treatment for glioblastoma multiforme (GBM), actinic prurigo, and rheumatoid arthritis."
What other investigations have been undertaken concerning 3-Dimensional Conformal Radiation Therapy?
"At the moment, 212 studies are underway to investigate 3-Dimensional Conformal Radiation Therapy. 24 of these experiments have advanced to Phase 3. Although research is concentrated in Seoul, Songpa there are 4763 other sites running clinical trials for this treatment."
Is 3-Dimensional Conformal Radiation Therapy a risk-free treatment option?
"Our team at Power has assigned 3-Dimensional Conformal Radiation Therapy a safety score of 1 as it is currently classified in Phase 1 clinical trials. This means there is limited data available regarding efficacy and precautionary measures."
What is the total number of individuals involved in this medical experiment?
"Affirmative. According to the information shared on clinicaltrials.gov, this medical research endeavour is actively seeking volunteers. The trial was initially put up for consideration on August 12th 2021 and has been recently updated on September 9th 2022. A total of 10 participants are being recruited from a single site in order to complete the study's conditions."
Is this trial still looking for participants?
"This study is still open to recruitment, as indicated on clinicaltrials.gov. It was initially posted on August 12th 2021 and the latest update came out on September 9th 2022."
Share this study with friends
Copy Link
Messenger